ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

24 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

13 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Leerink’s Global Healthcare Conference 2025

06 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

27 Feb 2025 07:00:01 By Nasdaq GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

27 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

21 Jan 2025 16:00:00 By Nasdaq GlobeNewswire

Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025

14 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

07 Nov 2024 09:01:00 By Nasdaq GlobeNewswire

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

09 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

16 Sep 2024 02:01:00 By Nasdaq GlobeNewswire

Adagene to Participate in Investor Conferences in September

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

25 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

12 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Adagene to Present at Investor Conferences in June

22 May 2024 15:45:00 By Nasdaq GlobeNewswire

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

29 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

07 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

27 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

09 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

16 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

04 Jan 2024 04:00:00 By Nasdaq GlobeNewswire